San Francisco, CA, United States of America

Andrew Michael Kenneth Pennell


Average Co-Inventor Count = 3.2

ph-index = 5

Forward Citations = 68(Granted Patents)


Location History:

  • San Carlos, CA (US) (2002 - 2004)
  • San Francisco, CA (US) (2002 - 2004)

Company Filing History:


Years Active: 2002-2004

Loading Chart...
6 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Andrew Michael Kenneth Pennell

Introduction

Andrew Michael Kenneth Pennell is a notable inventor based in San Francisco, CA. He has made significant contributions to the field of chemical compounds and their applications in medicine. With a total of six patents to his name, Pennell's work focuses on developing compounds that have therapeutic potential.

Latest Patents

Among his latest patents, Pennell has developed a compound of formula (I), where R represents C alkyl, halogen, or hydrogen. This compound is designed to be an agonist at the Adenosine A1 receptor. Additionally, he has patented methods of treating patients suffering from ischemic heart disease, peripheral vascular disease, or stroke. These methods involve administering a therapeutically effective amount of an adenosine derivative that exhibits minimal activity at the A3 receptor.

Career Highlights

Pennell is currently employed at Smithkline Beecham Corporation, where he continues to innovate in the field of pharmacology. His work has the potential to impact the treatment of various cardiovascular and central nervous system disorders.

Collaborations

Throughout his career, Pennell has collaborated with notable colleagues, including Colin David Eldred and Brian David Judkins. These partnerships have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Andrew Michael Kenneth Pennell's contributions to the field of chemical compounds and their medical applications highlight his role as an influential inventor. His innovative work continues to pave the way for advancements in therapeutic treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…